Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Drug Delivery in Cancer (2 pt) Technologies, Markets and Companies |
Jan 2012 | £2,590 | 100% |
| Transdermal Drug Delivery Technologies, Markets and Companies |
Jan 2012 | £1,945 | 98% |
| RNAi Technologies, Markets and Companies |
Jan 2012 | £2,590 | 98% |
| Competitive Outlook on Non-Antibody Based Cancer Vaccines | Aug 2006 | £1,620 | 97% |
| Nanobiotechnology (2 parts) Applications, Markets and Companies |
Jan 2012 | £3,240 | 97% |
| Targeted Therapies in Oncology A World Review |
Dec 2006 | £4,110 | 97% |
| U.S. Colorectal Cancer Market | Dec 2009 | £3,795 | 96% |
| Pain Therapeutics Technologies, Markets and Companies |
Jan 2012 | £2,590 | 95% |
| Cancer Therapies Global Market Opportunities |
Nov 2009 | £1,895 | 95% |
| Combination Devices - Application Landscape Technical Insights |
Jun 2011 | £4,110 | 94% |
| Stakeholder Opinions: Primary Brain Cancer | Jul 2007 | £2,400 | 93% |
| Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities |
Apr 2006 | £1,900 | 93% |
| Emerging Trends in Cancer Therapies (Small Molecule Drugs and Biologicals) (Technical Insights) | Jun 2008 | £4,110 | 93% |
| Market for Bioengineered Protein Drugs; The | Jan 2007 | £2,760 | 92% |
| Drug Targets for Breast Cancer | Jan 2006 | £1,095 | 92% |
| Global Cancer Drugs market 2009-2013 |
Jul 2010 | £950 | 92% |
| Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
Feb 2007 | £1,820 | 92% |
| Global Cancer Treatment Forecast to 2012 | Aug 2008 | £505 | 92% |
| Global Breast Cancer Drugs market 2009-2013 |
Jul 2010 | £950 | 91% |
| Global Cancer Drugs market 2009-2013 | Jul 2010 | £950 | 91% |
| Prostate Cancer Therapeutics A Global Market Perspective |
Nov 2009 | £1,895 | 91% |
| Cell therapy (2 parts) Technologies, Markets and Companies |
Jan 2012 | £3,560 | 91% |
| Currently Druggable in Colorectal Cancer A Drug Target Competitive Analysis |
Dec 2008 | £1,620 | 91% |
| Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) | Dec 2010 | £2,525 | 91% |
| Global Breast Cancer Drugs market 2009-2013 | Jul 2010 | £950 | 91% |
| RNA interference (RNAi) | Apr 2011 | £3,035 | 91% |
| Nanobiotechnology | Feb 2011 | £2,815 | 91% |
| The Impact of Nanotechnology on the Life Sciences and Healthcare Market to 2015 | Dec 2007 | £1,500 | 91% |
| Delivering New Biopharmaceutical Therapies Challenges & Opportunities |
Jan 2009 | £945 | 91% |
| Currently Druggable in Prostate Cancer A Drug Target Competitive Analysis |
Sep 2008 | £1,620 | 91% |
